A Phase 4 interventional study of Azacitidine in Myelodysplastic Syndromes, sponsored by Celgene. Completed at 11 sites in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-12-05.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 130 studies testing azacitidine in Myelodysplastic Syndromes — 13 open to participants now, 25 under way, 3 of them phase 3. Azacitidine · Myelodysplastic Syndromes.
Among the 130 studies testing azacitidine in Myelodysplastic Syndromes, this one is the 51st largest by enrollment of the 126 interventional ones that give a count, is one of 7 that started in 2010, is one of 3 in phase 4, and was the 41st registered.
1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.
Browse Myelodysplastic Syndromes studies →13 of the 130 studies testing azacitidine in Myelodysplastic Syndromes are open now, in 12 countries. Recruiting first, the newest first:
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18–70
City of Hope Medical Center · Sites in United States
Ages 18–75
Medical College of Wisconsin · Sites in United States
Ages 18+
Institut de Recherches Internationales Servier · Sites in United States, Australia, Brazil and 7 more countries
Ages 18+
Beijing 302 Hospital · Sites in China
Ages 18–70
By country, each count listing its studies:
Azacitidine: first FDA approval 2004 (VIDAZA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
130 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 50 · Phase 2 86 · Phase 3 12 · Phase 4 3
First in 2000; this study’s year is marked. 7 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 44 is close to the median of 40 across 1,611 interventional studies indexed under Myelodysplastic Syndromes.
Median enrollment 38 across the 126 interventional studies. Of the 88 that completed or were terminated, 42 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 130 have an industry lead sponsor. The 10 most frequent:
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
75 studies in Myelodysplastic Syndromes by Bristol-Myers Squibb: 4 open now, 9 under way, 5 of them phase 3. Of 63 finished, 20 (32%) have results posted.
Among the 75 studies in Myelodysplastic Syndromes by Bristol-Myers Squibb, this one is the 25th largest by enrollment of the 46 interventional ones that give a count, is one of 5 that started in 2010, is the only one in phase 4, and was the 24th registered.
Bristol-Myers Squibb’s Myelodysplastic Syndromes studies by the year they started, since 2001.
9 of the studies testing azacitidine in Myelodysplastic Syndromes that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06465953Phase 3Institut de Recherches Internationales ServierIvosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation | 2027-11-01 |
| NCT05788679Karolinska University HospitalA Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS | 2026-12 |
| NCT00392353National Cancer Institute (NCI)Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia | 2026-12-31 |
| NCT06502145Medical College of WisconsinIadademstat With Hypomethylating Agent in Patients With Myelodysplastic Syndrome | 2026-12-31 |
| NCT03862157M.D. Anderson Cancer CenterAzacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | 2027-01-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 130 studies testing azacitidine in Myelodysplastic Syndromes, from their registry updates:
Among Bristol-Myers Squibb’s 75 in Myelodysplastic Syndromes:
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to determine the effectiveness and safety of azacitidine in the treatment of Taiwanese subjects with higher-risk Myelodysplastic Syndrome (MDS).
The study has 3 phases which include the Screening Phase, the Treatment Phase, and the Post-Treatment Phase and outlined as follows:
Screening Phase:
Subjects will provide informed consent prior to undergoing any study-related procedures. Screening procedures are to take place within 28 days prior to the initiation of azacitidine treatment (Day 1, Cycle 1). Subject eligibility will be based on central pathology review. Bone marrow aspirate and bone marrow biopsy will be collected at screening and sent for morphological assessment by a central pathology reviewer prior to the subject receiving IP. The central pathology reviewer will document the MDS classification according to the FAB and WHO criteria (Appendix A and B, respectively).
A standard cytogenetic metaphase preparation will be prepared from the bone marrow aspirate and sent to the local or central laboratory (for sites without local analysis capability) for the cytogenetic analysis prior to receiving IP.
The IPSS score will be calculated using the central reviewer's pathology report for bone marrow blast percentage, local cytogenetic assessment for karyotype, and central laboratory report for number of cytopenias (Appendix D).
Treatment Phase:
The first dose of azacitidine for each subject begins on Day 1 of Cycle 1. All subjects will receive azacitidine 75 mg/m2/day SC for 7 days every 28 days for up to 6 cycles, unless they are discontinued from treatment. Visits during the treatment phase are to be scheduled weekly for the first 2 cycles, then every other week for all subsequent cycles throughout the rest of the study. Safety and efficacy measures are to be performed weekly, every other week, every 4 weeks, or at 24 weeks, depending on the procedure.
Post-Treatment Phase:
All discontinued subjects, regardless of reason for discontinuation, should undergo end-of-study procedures at the time of study discontinuation. Subjects will have a follow-up visit for the collection of adverse events up to 28 days after last IP dose.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Azacitidine 75 mg/m\^2/day Subcutaneous for 7 days Day every 28 days for up to 6 cycles
Drug: Azacitidine
Subjects will receive azacitidine 75 mg/m2/day SC for 7 days every 28 days for up to 6 cycles, unless they are discontinued from the treatment. In addition, subjects may receive best supportive care as needed, including antibiotics and transfusions, per Investigator discretion.
Percentage of Participants With a Hematologic Response Using International Working Group (IWG) Criteria for Myelodysplastic Syndrome (MDS) and Assessed by Investigator
Hematologic Response according to the 2000 International Working Group (IWG) response criteria for MDS was based on the Investigators determination and defined as: * Complete Response (CR): repeat bone marrow (BM) shows \<5% myeloblasts, and peripheral blood values lasting ≥ 2 months of hemoglobin (hgb) (\>110 g/L), neutrophils (≥1.5x10\^9/L), platelets (≥100x10\^9/L), blasts (0%) and no dysplasia * Partial Response (PR): same as CR for peripheral blood: BM shows blasts decrease by ≥ 50% or a less advanced FAB classification from pretreatment * Stable disease (SD): failure to achieve a PR, no evidence of progression for at least 2 months. * Failure: death during treatment or disease progression * Relapse After CR or PR: return to pretreatment BM blast percent or decrement of ≥ 50% from remission/response levels in granulocytes or platelets; or reduction in hgb by ≥20 g/L or transfusion dependence * Disease Progression: change in blast levels * Disease Transformation to AML
Time frame: Response assessed at end of cycle 6; through week 24; End of study
Percentage of Participants Showing Hematologic Improvement Using International Working Group (IWG Criteria for Hematologic Improvement Cheson 2000) Criteria for Myelodysplastic Syndrome (MDS) and Assessed by Sponsor
Hematologic improvements (HI) have 4 categories: 1. Erythroid response (HI-E): Major \>20g/L increase or transfusion independent. Minor- 10-20g/L increase or ≥50% decrease in transfusion requirements. 2. Platelet response (HI-P): Major absolute increase of ≥30x10\^9/L or platelet transfusion independence. Minor-≥50% increase. 3. Neutrophil response (HI-N): Major 100% increase or an absolute increase of \>0.5x10\^9/L. Minor-≥100% increase and absolute increase of \<0.5x10\^9/L 4. Progression or relapse after HI Overall hematological improvement (HI) was defined as any type (major or minor) of improvement of HI-E, HI-P, or HI-N. Criteria: Pretreatment=hemoglobin \<100g/L or RBC transfusion-dependent, platelet count \<100x10\^9/L or platelet transfusion dependent, absolute neutrophil count \<1.5x10\^9/L. Sponsor's determination was derived using clinically relevant data. Denominator for progression/relapse after HI included participants who had achieved HI.
Time frame: Response assessed at end of cycle 6; through week 24; End of study
Number of Red Blood Cell (RBC) Transfusions by Cycle
The number of transfusions received 56 days prior to treatment and during study were standardized per 28 days and summarized by cycle for RBCs. The formula for standardizing per 28 days was: \[(# of transfusions in the measurement period / length of the measurement period (days)) x 28\], where the measurement period was either baseline or the relevant cycle length. For each participant the overall post-baseline average was calculated as the average of # of RBC transfusions per cycle.
Time frame: Up to week 24;The on-treatment period was considered the period from the date of the first dose to the last treatment study visit.
Number of Platelet Transfusions by Cycle
The number of transfusions received 56 days prior to treatment and during study was standardized per 28 days and summarized by cycle for platelets. The formula for standardizing per 28 days was: \[(# of transfusions in the measurement period / length of the measurement period (days)) x 28\], where the measurement period was either baseline or the relevant cycle length. For each participant the overall post-baseline average was calculated as the average of # of platelet transfusions per cycle.
Time frame: Up to week 24; The on-treatment period was considered the period from the date of the first dose to the last treatment study visit.
Number of Infections (Post-baseline Average) Requiring Intravenous Antibiotics, Anti-fungals, or Antivirals Per 28 Days
The on-treatment adverse event of infection requiring IV antibiotics, antifungals, or antivirals per 28 days/cycle. The overall post-baseline average is the average of number of infections requiring IV antibiotics or IV antiviral per 28 days/cycle. For each participant the overall post-baseline average was calculated as the average of # of infections requiring IV antibiotics or IV antiviral per 28 days per cycle.
Time frame: Up to week 24; The on-treatment period was considered the period from the date of the first dose to the last treatment study visit.
Number of Participants With Adverse Events (AE)
An AE that resulted in any of the following outcomes was defined as a serious adverse event (SAE): * Death; * Life-threatening event; * Any inpatient hospitalization or prolongation of existing hospitalization; * Persistent or significant disability or incapacity; * Congenital anomaly or birth defect; * Any other important medical event. The severity of an AE was evaluated by the investigator according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) (Version 4.0) where Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening and Grade 5 = Death. Treatment Emergent AEs (TEAE) were defined as AEs with an onset date on or after the first dose of study drug and within 28 days after the date of the last dose. In addition, any AE that occurred beyond this timeframe and that was assessed by the investigator as possibly related to study drug was considered a TEAE.
Time frame: From the first dose of study drug through 28 days after completion of/discontinuation from the study (maximum time on study drug 244 days)
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC∞) of Azacitidine
Area under the plasma concentration-time curve from time zero to infinity (AUC∞) following multiple doses of Azacitidine on Day 7; if possible, the area under the concentration-time curve from time zero to infinity, calculated by the linear trapezoidal rule and extrapolated to infinity was calculated according to the following equation: AUC∞ = AUCt + (Ct/ λz ), where Ct is the last quantifiable concentration. No AUC extrapolation was performed with unreliable λz. If % AUC extrapolated is ≥ 25%, AUC∞ was not reported.
Time frame: Timeframe: Day 7 pre-dose and at 0.25, 0.5, 1, 2, 3, 4, 6, 8 hours post-dose
Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUCt) of Azacitidine
Area under the plasma concentration-time curve from time zero to the last quantifiable time point, calculated by the linear trapezoidal rule when concentrations are increasing and the logarithmic trapezoidal method when concentrations are decreasing.
Time frame: Timeframe: Day 7 pre-dose and at 0.25, 0.5, 1, 2, 3, 4, 6, 8 hours post-dose
Maximum Observed Plasma Concentration (Cmax) of Azacitidine
The observed maximum plasma concentration obtained directly from the observed concentration versus time data.
Time frame: Timeframe: Day 7 pre-dose and at 0.25, 0.5, 1, 2, 3, 4, 6, 8 hours post-dose
Time to Maximum Plasma Concentration (Tmax) of Azacitidine
Time to maximum observed plasma concentration obtained directly from the observed concentration versus time data.
Time frame: Timeframe: Day 7 pre-dose and at 0.25, 0.5, 1, 2, 3, 4, 6, 8 hours post-dose
Terminal Phase of Half-life (T1/2) of Azacitidine
The apparent terminal half-life was calculated according to the following equation t½ = 0.693/λz.
Time frame: Timeframe: Day 7 pre-dose at 0.25, 0.5, 1, 2, 3, 4, 6, 8 hours post-dose
Apparent Total Plasma Clearance (CL/F) of Azacitidine
Apparent total plasma clearance (CL/F) of Azacitidine was calculated as Dose/AUC∞
Time frame: Timeframe: Days 5 and 6 at predose and Day 7 (pre-dose) at 0.25, 0.5, 1, 2, 3, 4, 6, 8 hours post-dose
Apparent Volume of Distribution (Vd/F) of Azacitidine
Apparent volume of distribution, was calculated according to the equation: Vd/F = (CL/F)/λz
Time frame: Timeframe: Day 7 pre-dose and at 0.25, 0.5, 1, 2, 3, 4, 6, 8 hours post-dose
Participants' Red Blood Cell (RBC) Transfusion Status for Participants Who Were Transfusion Dependent at Baseline
A participant was considered transfusion dependent at baseline if the participant had one or more Red Blood Cell transfusions during the 56 days prior to first dose. During the study, a participant was considered transfusion independent during the on-treatment period if the participant had no transfusions during any 56 consecutive days or more (e.g., Day 1 through 56, Day 2 through 57, etc). Otherwise, they were considered transfusion dependent. The total N=44, but 1 participant can only be dependent or independent at baseline for each type of transfusion (ie, total = 44: RBC dependent at BL=32, RBC independent at BL=12)
Time frame: Baseline to Cycle 6; The on-treatment period was considered the period from the date of the first dose to the last treatment study visit
Participants' Red Blood Cell (RBC) Transfusion Status for Participants Who Were Transfusion Independent at Baseline
A participant was considered RBC transfusion-independent at baseline if the participant had no RBC transfusions during the 56 days prior to first dose. During the study, a participant was considered transfusion independent during the on-treatment period if the participant had no RBC transfusions during any 56 consecutive days or more (eg, Days 1 through 56, Days 2 through 57, etc.). Otherwise, they were considered transfusion dependent. The total N=44, but 1 participant can only be dependent or independent at baseline for each type of transfusion (ie, total = 44: RBC dependent at BL=32, RBC independent at BL=12)
Time frame: Baseline to Cycle 6; The on-treatment period was considered the period from the date of the first dose to the last treatment study visit.
Participants' Platelet Transfusion Status for Participants Who Were Transfusion Dependent at Baseline
A participant was considered platelet transfusion dependent at baseline if the participant had one or more platelet transfusions during the 56 days prior to first dose. During the study, a participant was considered platelet transfusion independent during the on-treatment period if the participant had no platelet transfusions during any 56 consecutive days or more (eg, Days 1 through 56, Days 2 through 57, etc.). Otherwise, they were considered platelet transfusion dependent. The total N=44, but 1 participant can only be dependent or independent at baseline for each type of transfusion (ie, total = 44: platelet dependent at BL=18, platelet independent at BL=26)
Time frame: Baseline to Cycle 6; The on-treatment period was considered the period from the date of the first dose to the last treatment study visit.
Participants' Platelet Transfusion Status for Participants Who Were Transfusion Independent at Baseline
A participant was considered platelet transfusion independent at baseline if the participant had no platelet transfusions during the 56 days prior to first dose. During the study, a participant was considered platelet transfusion independent during the on-treatment period if the participant had no platelet transfusions during any 56 consecutive days or more (eg, Days 1 through 56, Days 2 through 57, etc.). Otherwise, they were considered platelet transfusion dependent. The total N=44, but 1 participant can only be dependent or independent at baseline for each type of transfusion (ie, total = 44: platelet dependent at BL=18, platelet independent at BL=26)
Time frame: Baseline to Cycle 6; The on-treatment period was considered the period from the date of the first dose to the last treatment study visit.
The study was conducted at nine investigational sites within Taiwan. The purpose of the current study was to evaluate the efficacy, safety, and steady-state Pharmacokinetic (PK) profile of subcutaneous (SC) azacitidine given at a dose of 75 mg/m\^2/day for 7 days in Taiwanese participants with higher-risk Myelodysplastic Syndrome (MDS).
| Milestone | Azacitidine |
|---|---|
| Started | 44 |
| Completed | 25 |
| Not completed | 19 |
| Withdrew: Adverse event | 6 |
| Withdrew: Disease progression | 3 |
| Withdrew: Withdrawal by subject | 3 |
| Withdrew: Death | 4 |
| Withdrew: Treatment failure | 2 |
| Withdrew: Physician decision | 1 |
Hematologic Response according to the 2000 International Working Group (IWG) response criteria for MDS was based on the Investigators determination and defined as: * Complete Response (CR): repeat bone marrow (BM) shows \<5% myeloblasts, and peripheral blood values lasting ≥ 2 months of hemoglobin (hgb) (\>110 g/L), neutrophils (≥1.5x10\^9/L), platelets (≥100x10\^9/L), blasts (0%) and no dysplasia * Partial Response (PR): same as CR for peripheral blood: BM shows blasts decrease by ≥ 50% or a less advanced FAB classification from pretreatment * Stable disease (SD): failure to achieve a PR, no evidence of progression for at least 2 months. * Failure: death during treatment or disease progression * Relapse After CR or PR: return to pretreatment BM blast percent or decrement of ≥ 50% from remission/response levels in granulocytes or platelets; or reduction in hgb by ≥20 g/L or transfusion dependence * Disease Progression: change in blast levels * Disease Transformation to AML
| percentage of participants | Azacitidine |
|---|---|
| Overall (CR+PR) | 0 (0.0 to 8.0) |
| Overall (CR+PR+SD) | 63.6 (47.8 to 77.6) |
| Complete Remission (CR) | 0.0 (0.0 to 8.0) |
| Partial Remission (PR) | 0.0 (0.0 to 8.0) |
| Stable Disease (SD) | 63.6 (47.8 to 77.6) |
| Disease Progression (DP) | 2.3 (0.1 to 12.0) |
| Transformation to AML | 4.5 (0.6 to 15.5) |
| Failure | 4.5 (0.6 to 15.5) |
| No Response Assessed | 25.0 (13.2 to 40.3) |
Hematologic improvements (HI) have 4 categories: 1. Erythroid response (HI-E): Major \>20g/L increase or transfusion independent. Minor- 10-20g/L increase or ≥50% decrease in transfusion requirements. 2. Platelet response (HI-P): Major absolute increase of ≥30x10\^9/L or platelet transfusion independence. Minor-≥50% increase. 3. Neutrophil response (HI-N): Major 100% increase or an absolute increase of \>0.5x10\^9/L. Minor-≥100% increase and absolute increase of \<0.5x10\^9/L 4. Progression or relapse after HI Overall hematological improvement (HI) was defined as any type (major or minor) of improvement of HI-E, HI-P, or HI-N. Criteria: Pretreatment=hemoglobin \<100g/L or RBC transfusion-dependent, platelet count \<100x10\^9/L or platelet transfusion dependent, absolute neutrophil count \<1.5x10\^9/L. Sponsor's determination was derived using clinically relevant data. Denominator for progression/relapse after HI included participants who had achieved HI.
| percentage of participants | Azacitidine |
|---|---|
| Any improvement | 50.0 (34.6 to 65.4) |
| Hematologic Improvement-E (major) | 31.8 (18.6 to 47.6) |
| Hematologic Improvement-E (minor) | 9.1 (2.5 to 21.7) |
| Hematologic Improvement-P (major) | 37.8 (22.5 to 55.2) |
| Hematologic Improvement-P (minor) | 0 (0 to 9.5) |
| Hematologic Improvement-N (major) | 7.1 (0.9 to 23.5) |
| Hematologic Improvement-N (minor) | 0 (0 to 12.3) |
| Progression/relapse after HI | 27.3 (10.7 to 50.2) |
A participant was considered transfusion dependent at baseline if the participant had one or more Red Blood Cell transfusions during the 56 days prior to first dose. During the study, a participant was considered transfusion independent during the on-treatment period if the participant had no transfusions during any 56 consecutive days or more (e.g., Day 1 through 56, Day 2 through 57, etc). Otherwise, they were considered transfusion dependent. The total N=44, but 1 participant can only be dependent or independent at baseline for each type of transfusion (ie, total = 44: RBC dependent at BL=32, RBC independent at BL=12)
| percentage of participants | Azacitidine |
|---|---|
| Baseline Dependent: On-Treatment Independent | 37.5 ± 1.97 |
| Baseline Dependent; On-Treatment Dependent | 62.5 ± 2.47 |
A participant was considered RBC transfusion-independent at baseline if the participant had no RBC transfusions during the 56 days prior to first dose. During the study, a participant was considered transfusion independent during the on-treatment period if the participant had no RBC transfusions during any 56 consecutive days or more (eg, Days 1 through 56, Days 2 through 57, etc.). Otherwise, they were considered transfusion dependent. The total N=44, but 1 participant can only be dependent or independent at baseline for each type of transfusion (ie, total = 44: RBC dependent at BL=32, RBC independent at BL=12)
| percentage of participants | Azacitidine |
|---|---|
| Baseline Independent; On-Treatment Independent | 75.0 (42.8 to 94.5) |
| Baseline Independent; On-Treatment Dependent | 25.0 (5.5 to 57.2) |
The number of transfusions received 56 days prior to treatment and during study were standardized per 28 days and summarized by cycle for RBCs. The formula for standardizing per 28 days was: \[(# of transfusions in the measurement period / length of the measurement period (days)) x 28\], where the measurement period was either baseline or the relevant cycle length. For each participant the overall post-baseline average was calculated as the average of # of RBC transfusions per cycle.
| Transfusions | Azacitidine |
|---|---|
| Baseline (N = 44) | 1.3 ± 1.97 |
| Overall Post-Baseline Average (N = 44) | 2.4 ± 2.47 |
| overall Change from Baseline ( N = 44) | 1.0 ± 2.59 |
| Cycle 1 ( N = 44) | 2.5 ± 2.27 |
| Cycle 2 | 2.3 ± 2.03 |
| Cycle 3 | 2.2 ± 2.90 |
| Cycle 4 | 1.5 ± 2.11 |
| Cycle 5 | 1.4 ± 2.59 |
| Cycle 6 | 1.9 ± 3.96 |
A participant was considered platelet transfusion dependent at baseline if the participant had one or more platelet transfusions during the 56 days prior to first dose. During the study, a participant was considered platelet transfusion independent during the on-treatment period if the participant had no platelet transfusions during any 56 consecutive days or more (eg, Days 1 through 56, Days 2 through 57, etc.). Otherwise, they were considered platelet transfusion dependent. The total N=44, but 1 participant can only be dependent or independent at baseline for each type of transfusion (ie, total = 44: platelet dependent at BL=18, platelet independent at BL=26)
| percentage of participants | Azacitidine |
|---|---|
| Baseline Dependent; On-Treatment Independent | 38.9 (17.3 to 64.3) |
| Baseline Dependent; On-Treatment Dependent | 61.1 (35.7 to 82.7) |
A participant was considered platelet transfusion independent at baseline if the participant had no platelet transfusions during the 56 days prior to first dose. During the study, a participant was considered platelet transfusion independent during the on-treatment period if the participant had no platelet transfusions during any 56 consecutive days or more (eg, Days 1 through 56, Days 2 through 57, etc.). Otherwise, they were considered platelet transfusion dependent. The total N=44, but 1 participant can only be dependent or independent at baseline for each type of transfusion (ie, total = 44: platelet dependent at BL=18, platelet independent at BL=26)
| percentage of particpants | Azacitidine |
|---|---|
| Baseline Independent: On-Treatment Independent | 76.9 (56.4 to 91.0) |
| Baseline Independent; On-Treatment Dependent | 23.1 (9.0 to 43.6) |
The number of transfusions received 56 days prior to treatment and during study was standardized per 28 days and summarized by cycle for platelets. The formula for standardizing per 28 days was: \[(# of transfusions in the measurement period / length of the measurement period (days)) x 28\], where the measurement period was either baseline or the relevant cycle length. For each participant the overall post-baseline average was calculated as the average of # of platelet transfusions per cycle.
| Transfusions | Azacitidine |
|---|---|
| Baseline ( N = 44) | 0.9 ± 2.40 |
| Overall Post-Baseline Average ( N= 44) | 2.7 ± 3.56 |
| OverallChange from Baseline ( N = 44) | 1.8 ± 3.53 |
| Cycle 1 ( N = 44) | 2.6 ± 3.38 |
| Cycle 2 | 2.3 ± 3.28 |
| Cycle 3 | 3.0 ± 4.85 |
| Cycle 4 | 1.6 ± 2.89 |
| Cycle 5 | 1.9 ± 3.61 |
| Cycle 6 | 2.7 ± 6.01 |
The on-treatment adverse event of infection requiring IV antibiotics, antifungals, or antivirals per 28 days/cycle. The overall post-baseline average is the average of number of infections requiring IV antibiotics or IV antiviral per 28 days/cycle. For each participant the overall post-baseline average was calculated as the average of # of infections requiring IV antibiotics or IV antiviral per 28 days per cycle.
| Infections per cycle | Azacitidine |
|---|---|
| Baseline | 0.1 ± 0.51 |
| Overall Post Baseline | 0.5 ± 0.79 |
| Overall Change from Baseline | 0.4 ± 0.98 |
| Cycle 1 | 0.5 ± 0.85 |
| Cycle 2 | 0.4 ± 0.61 |
| Cycle 3 | 0.4 ± 0.82 |
| Cycle 4 | 0.1 ± 0.39 |
| Cycle 5 | 0.1 ± 0.38 |
| Cycle 6 | 0.2 ± 0.66 |
An AE that resulted in any of the following outcomes was defined as a serious adverse event (SAE): * Death; * Life-threatening event; * Any inpatient hospitalization or prolongation of existing hospitalization; * Persistent or significant disability or incapacity; * Congenital anomaly or birth defect; * Any other important medical event. The severity of an AE was evaluated by the investigator according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) (Version 4.0) where Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening and Grade 5 = Death. Treatment Emergent AEs (TEAE) were defined as AEs with an onset date on or after the first dose of study drug and within 28 days after the date of the last dose. In addition, any AE that occurred beyond this timeframe and that was assessed by the investigator as possibly related to study drug was considered a TEAE.
| participants | Azacitidine |
|---|---|
| ≥ 1 TEAE | 44 |
| ≥ 1 NCI Grade 3 or 4 TEAE | 37 |
| ≥ TEAE related to study drug | 34 |
| ≥ 1 NCI Grade 3 or 4 TEAE related to study drug | 22 |
| ≥ 1 serious TEAE | 28 |
| ≥ 1 NCI CTC Grade 3 or 4 serious TEAE | 24 |
| ≥ 1 serious TEAE related to study drug | 14 |
| TEAE leading to discontinuation of study drug | 8 |
| TEAE leading to study drug dose reduction | 7 |
| TEAE leading to study drug dose interruption | 16 |
| TEAE leading to dose reduction or interruption | 20 |
| TEAE leading to death | 7 |
Area under the plasma concentration-time curve from time zero to infinity (AUC∞) following multiple doses of Azacitidine on Day 7; if possible, the area under the concentration-time curve from time zero to infinity, calculated by the linear trapezoidal rule and extrapolated to infinity was calculated according to the following equation: AUC∞ = AUCt + (Ct/ λz ), where Ct is the last quantifiable concentration. No AUC extrapolation was performed with unreliable λz. If % AUC extrapolated is ≥ 25%, AUC∞ was not reported.
| ng*h/mL | Azacitidine |
|---|---|
| Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC∞) of Azacitidine | 859.1 ± 23.4 |
Area under the plasma concentration-time curve from time zero to the last quantifiable time point, calculated by the linear trapezoidal rule when concentrations are increasing and the logarithmic trapezoidal method when concentrations are decreasing.
| ng*h/mL | Azacitidine |
|---|---|
| Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUCt) of Azacitidine | 852.8 ± 23.3 |
The observed maximum plasma concentration obtained directly from the observed concentration versus time data.
| ng/mL | Azacitidine |
|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Azacitidine | 972.3 ± 44.0 |
Time to maximum observed plasma concentration obtained directly from the observed concentration versus time data.
| hours | Azacitidine |
|---|---|
| Time to Maximum Plasma Concentration (Tmax) of Azacitidine | 0.29 ± 27.65 |
The apparent terminal half-life was calculated according to the following equation t½ = 0.693/λz.
| hours | Azacitidine |
|---|---|
| Terminal Phase of Half-life (T1/2) of Azacitidine | 1.0 ± 38.7 |
Apparent total plasma clearance (CL/F) of Azacitidine was calculated as Dose/AUC∞
| L/hr | Azacitidine |
|---|---|
| Apparent Total Plasma Clearance (CL/F) of Azacitidine | 149.6 ± 29.6 |
Apparent volume of distribution, was calculated according to the equation: Vd/F = (CL/F)/λz
| Liters | Azacitidine |
|---|---|
| Apparent Volume of Distribution (Vd/F) of Azacitidine | 205.3 ± 32.4 |
Collected over From the first dose of study drug through 28 days after completion of/discontinuation from the study (maximum time on study drug 244 days). Non-serious events are listed at a 5.0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Azacitidine | — | 28/44 (63.6%) | 44/44 (100%) |
| Event | Azacitidine |
|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 10/44 |
| PneumoniaInfections and infestations | 8/44 |
| PyrexiaGeneral disorders | 6/44 |
| SepsisInfections and infestations | 4/44 |
| NeutropeniaBlood and lymphatic system disorders | 3/44 |
| Haemorrhage intracranialNervous system disorders | 3/44 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 3/44 |
| ThrombocytopeniaBlood and lymphatic system disorders | 2/44 |
| CellulitisInfections and infestations | 2/44 |
| Postoperative wound infectionInfections and infestations | 2/44 |
| Event | Azacitidine |
|---|---|
| NeutropeniaBlood and lymphatic system disorders | 23/44 |
| PyrexiaGeneral disorders | 23/44 |
| CoughRespiratory, thoracic and mediastinal disorders | 22/44 |
| AnaemiaBlood and lymphatic system disorders | 19/44 |
| LeukopeniaBlood and lymphatic system disorders | 19/44 |
| ConstipationGastrointestinal disorders | 17/44 |
| DiarrhoeaGastrointestinal disorders | 17/44 |
| NauseaGastrointestinal disorders | 17/44 |
| VomitingGastrointestinal disorders | 17/44 |
| DizzinessNervous system disorders | 17/44 |
The intention-to-treat (ITT) population was defined as all enrolled participants.
| Age, Continuous(years) | Azacitidine |
|---|---|
| Mean | 62.3 ± 11.76 |
| Sex: Female, Male(Participants) | Azacitidine |
|---|---|
| Female | 17 |
| Male | 27 |
| Race/Ethnicity, Customized(Participants) | Azacitidine |
|---|---|
| Asian | 44 |
| Myelodysplastic Syndrome (MDS) French-American-British (FAB) Classification(Participants) | Azacitidine |
|---|---|
| Refractory anemia with excess blasts (RAEB) | 35 |
| RAEB in transformation | 7 |
| Chronic myelomonocytic leukemia (Modified CMML) | 2 |
| Acute myelogenous leukemia (AML) | 0 |
| World Health Organization (WHO) Classification(Participants) | Azacitidine |
|---|---|
| Refractory anemia with excess blasts (RAEB-1) | 15 |
| Refractory anemia with excess blasts (RAEB-2) | 23 |
| Acute myelogenous leukemia (AML) | 5 |
| Chronic myelomonocytic leukemia (CMML -1) | 1 |
| Chronic myelomonocytic leukemia (CMML-2) | 0 |
| Refractory anemia (RA) | 0 |
| RA with ringed sideroblasts (RARS) | 0 |
| Refractory Cytopenia Multilineage Dysplasia (RCMD) | 0 |
| Myelodysplastic Syndrome - Unclassified (MDS-U) | 0 |
| International Prognostic Scoring System (IPSS)(Participants) | Azacitidine |
|---|---|
| Low risk (0) | 0 |
| Intermediate-1 (0.5 - 1.0) | 2 |
| Intermediate-2 (1.5 - 2.0) | 16 |
| High Risk (≥ 2.5) | 26 |
Ran from Oct 2010 to primary completion in May 2013, 31 months.
Results were first posted in Jun 2014, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Azacitidine